Industry Reports

Sales grow by 35.0% to CHF 239.1 million EBITDA rises from CHF 53.0 million to CHF 75.5 million and a margin of 31.6%. Operating income (EBIT) increases from CHF 40.3 million to CHF 61.9 million and a margin...

Samsung Biologics , a leading contract development and manufacturing organization, announced strong financial results for the secondquarter of fiscal 2021. John Rim, CEO of Samsung Biologics, stated, “The second-quarter financial performance demonstrates our ability to maintain steady operations despite the...

Samsung Biologics, the world’s leading contract development and manufacturing organization (CDMO), published its first annual sustainability report, consolidating the company’s policies for an enhanced ESG management system and related plans. The report focuses on the company’s commitment to taking...

Virtual clinical development specialist, Phesi Inc., has today released findings from a significant analysis of COVID-19 patient profiles; based on data from 166,239 COVID-19 patients, from 523 cohorts/trial arms. The data includes patients from 56 countries, including the USA,...

Randomized clinical trials have demonstrated that teduglutide, a glucagon-like peptide-2 (GLP-2) analog, improves intestinal absorption in patients with short bowel syndrome (SBS) with parenteral support (PS) dependence.1 Our objective was to assess real-world evidence of teduglutide effectiveness and safety...

A global industry survey conducted by Nutrify, the world’s first and only nutraceuticals i2c (ideas to commercialization) platform, has found that there is growing optimism around the food and nutrition industry globally. Nutraceutical industry leaders from the USA, Israel,...

The Pistoia Alliance, a global, not-for-profit alliance that advocates for greater collaboration in life sciences and healthcare R&D, announced findings from a survey conducted at its spring conference. Respondents believe that emerging technologies including AI and blockchain will receive...